Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001181431-12-051916
Filing Date
2012-09-24
Accepted
2012-09-24 18:14:13
Documents
1
Period of Report
2012-09-20

Document Format Files

Seq Description Document Type Size
1 FORM 4 rrd356817.html 4  
1 FORM 4 rrd356817.xml 4 4582
  Complete submission text file 0001181431-12-051916.txt   6746
Mailing Address LICHTSTRASSE 35 CH-4002 BASEL V8
Business Address LICHTSTRASSE 35 CH-4002 BASEL V8 212-830-2474
NOVARTIS PHARMA AG (Reporting) CIK: 0001030617 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-50743 | Film No.: 121107442

Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Reporting) CIK: 0001114448 (see all company filings)

State of Incorp.: V8 | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 000-50743 | Film No.: 121107443
SIC: 2834 Pharmaceutical Preparations

Mailing Address 300 THIRD STREET CAMBRIDGE MA 02142
Business Address 300 THIRD STREET CAMBRIDGE MA 02142 (617) 551-8200
ALNYLAM PHARMACEUTICALS, INC. (Issuer) CIK: 0001178670 (see all company filings)

EIN.: 770602661 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations